Retatrutide Safety, Tolerability & Risk Considerations

Not medical advice. Safety profile summaries are based on investigational data and may evolve with ongoing trials.

Commonly Reported Adverse Events (Trials)

• Gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, abdominal discomfort, especially during dose escalation.
• Potential class-consistent issues under evaluation: gallbladder events, pancreatitis concerns, heart-rate changes.
• Symptoms and incidence vary by dose, titration schedule, and population.

Unresolved Questions

• Long-term cardiovascular outcomes and rare events.
• Optimal titration strategies to balance efficacy and tolerability.
• Population-specific safety (e.g., hepatic, renal, high-risk cohorts).

Why We Warn Against DIY or Black-Market Use

Because retatrutide is investigational, any product advertised direct-to-consumer as
“GLP3 Retatrutide Peptide”, “Triple G”, or similar is highly suspect.
See our dedicated
Black Market Warning.

When approved data matures, GLP3 Weight Loss will update this page to reflect verified safety information.